BAL PHARMA LTD.
Latest filings
- Compliance certificate for share dematerialisation for Q2 FY26 · Compliance
- Bal Pharma directors swap executive roles effective Oct 1, 2026 · Management Changes
- Bal Pharma 39th AGM: All 7 resolutions passed, Rs 1.20 dividend approved · Compliance
Snapshot
What the business is, and whether it's a good one at a fair price.
Manufactures pharmaceutical products, with consolidated FY26 revenue of Rs 311.66 crore. The company is building a greenfield active pharmaceutical ingredient (API) manufacturing facility at Yadagiri, Karnataka, with a project cost of about Rs 300 crore, for which land has been acquired and environmental clearance obtained. Materials and inputs make up 51.6% of revenue and employee costs 21.3%, making raw materials the largest cost line. FY26 consolidated net profit was Rs 6.32 crore and EBITDA margin 10.86%. Depreciation is 3.6% of revenue and other operating expenses 17.8% of revenue. The board recommended a final dividend of Rs 1.20 per equity share (12% on Rs 10 face value) for FY26.
Scorecard
Measured from the filed financials, judged against its Pharmaceuticals peers · as of FY26 — not investment advice
Strengths
Concerns
Charts
How has the market priced it — with filings on the timeline?
BALPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Peers
How does it stack up on valuation, returns and growth?
Loading peers…
Financials
Quarterly & annual P&L, balance sheet, cash flow, ratios and segments.
Loading financials…
Ownership
Who owns it — and is the promoter stake clean?
Loading shareholding…
Sign up to see the full company file
Governance, sustainability, compliance, earnings calls, presentations, events, reactions and the full filings feed — free with an account.
Common questions
Answered from BAL PHARMA LTD.'s filed financials and exchange disclosures
What does BAL PHARMA LTD. do?
BAL PHARMA LTD. is a Pharmaceuticals & Biotechnology company listed on NSE and BSE, trading under the symbol BALPHARMA.
Is BAL PHARMA LTD. profitable?
Yes. Over the trailing twelve months BAL PHARMA LTD. reported a net profit of ₹7.25 Cr on revenue of ₹334 Cr.
Does BAL PHARMA LTD. pay a dividend?
Yes. The dividend yield is 0.01% at the current price. It paid out 0% of its profit as dividend in FY26.
Is BAL PHARMA LTD. debt-free?
No. It reported borrowings of ₹160 Cr on its 31 Mar 2026 balance sheet, or net debt of ₹157 Cr after cash. Debt stands at 1.94× equity. That is higher than 97% of its 166 Pharmaceuticals peers.
Is BAL PHARMA LTD. expensive compared with its peers?
On trailing P/E, BAL PHARMA LTD. ranks 50 of 158 in Pharmaceuticals — cheaper than 69% of them, against an industry median of 31.2×. This is a position, not a valuation judgement.
How much does the BAL PHARMA LTD. share price move in a day?
On a typical session BAL PHARMA LTD. moves 1.27% — that is the median absolute close-to-close move across its last 268 trading days. MarketPing measures each filing's price reaction against it.
Where can I track BAL PHARMA LTD.'s announcements?
Every NSE and BSE filing by BAL PHARMA LTD. appears on this page, AI-summarised, alongside the price reaction that followed it. Follow the company to get each new filing on WhatsApp within minutes.
Figures are as last reported and may lag the latest filing. Not investment advice.